DAXOR CORPORATION - CLOSED END FUND

New Studies Validating the Uniqueness of the BVA-100® Blood Test for Heart Failure Patients Compared to Pressure Measures

03 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Daxor Corporation to Exhibit at the Annual Scientific Meeting of the Heart Failure Society of America

26 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Daxor Corporation to Attend the H.C. Wainwright 24th Annual Global Investment Conference

06 Sep 2022 17:05:00 By Nasdaq GlobeNewswire

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

29 Aug 2022 08:00:00 By Nasdaq GlobeNewswire

Daxor Corporation Reports a 92.6 Percent Revenue Increase in Diagnostic Operating Division in Form N-CSR Filing for the Six Months Ended June 30, 2022

25 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

Daxor Corporation to Report First Half 2022 Financial Results on Thursday, August 25, 2022, and Provide Corporate Update

24 Aug 2022 16:40:00 By Nasdaq GlobeNewswire

Daxor Corporation Announces a 49.4% Increase In Its Single-Use Diagnostic Kits Year-Over-Year and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.

27 Jul 2022 08:00:02 By Nasdaq GlobeNewswire

DAXOR CORPORATION ANNOUNCES PARTNERSHIP WITH MEDAXIOM TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)

21 Jul 2022 08:00:01 By Nasdaq GlobeNewswire

DAXOR COMPLETES NIH FUNDED I-CORPS PROGRAM FOR COMMERCIALIZATION OF CLINICAL DECISION SUPPORT SOFTWARE

18 Jul 2022 08:00:01 By Nasdaq GlobeNewswire

DAXOR ANNOUNCES COOPERATIVE RESEARCH AND DEVELOPMENT PHASE II AGREEMENT WITH THE UNIFORMED ARMED SERVICES UNIVERSITY FOR THE DEVELOPMENT OF A NON-NUCLEAR BLOOD VOLUME ANALYSIS (BVA) DEVICE

27 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Daxor Corporation to Showcase the Benefits of BVA-100® Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 18th Annual Meeting

13 Jun 2022 08:00:02 By Nasdaq GlobeNewswire

Daxor’s Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients

25 May 2022 08:00:01 By Nasdaq GlobeNewswire

Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference

12 May 2022 08:00:01 By Nasdaq GlobeNewswire

New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients with Advanced Heart Failure Supported with Left Ventricular Assist Device

02 May 2022 08:00:01 By Nasdaq GlobeNewswire

New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure

06 Apr 2022 08:00:00 By Nasdaq GlobeNewswire

Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference

23 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

01 Mar 2022 09:00:04 By Nasdaq GlobeNewswire

Daxor Corporation Announces $1.35 Per Share NAV Increase and Files Annual Report for Fiscal 2021

01 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Study Demonstrates Importance and Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart Failure

17 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Daxor Corporation Commences Trading on The NASDAQ Capital Market

02 Feb 2022 08:00:01 By Nasdaq GlobeNewswire